Deferred Tax Assets, Valuation Allowance of Outlook Therapeutics, Inc. from 30 Sep 2015 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary: Outlook Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 30 Sep 2015 to 30 Sep 2025.
Outlook Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 30 Sep 2025 was $145,880,866, a 5.1% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Outlook Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$145,880,866	+$7,121,356	+5.1%	30 Sep 2025	10-K	19 Dec 2025	2025	FY
Q3 2024	$138,759,510	+$19,034,432	+16%	30 Sep 2024	10-K	19 Dec 2025	2025	FY
Q3 2023	$119,725,078	+$17,094,828	+17%	30 Sep 2023	10-K	27 Dec 2024	2024	FY
Q3 2022	$102,630,250	+$21,180,878	+26%	30 Sep 2022	10-K	22 Dec 2023	2023	FY
Q3 2021	$81,449,372	+$16,346,970	+25%	30 Sep 2021	10-K	29 Dec 2022	2022	FY
Q3 2020	$65,102,402	-$3,865,284	-5.6%	30 Sep 2020	10-K	23 Dec 2021	2021	FY
Q3 2019	$68,967,686	+$7,073,727	+11%	30 Sep 2019	10-K	23 Dec 2020	2020	FY
Q3 2018	$61,893,959	-$8,008,487	-11%	30 Sep 2018	10-K	19 Dec 2019	2019	FY
Q3 2017	$69,902,446	+$17,165,342	+33%	30 Sep 2017	10-K	18 Dec 2018	2018	FY
Q3 2016	$52,737,104	+$14,042,309	+36%	30 Sep 2016	10-K	29 Dec 2017	2017	FY
Q3 2015	$38,694,795			30 Sep 2015	10-K	29 Dec 2016	2016	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.